Hemab Therapeutics/X
Sep 2, 2025, 12:50
New COO at Hemab Therapeutics: Anant Murthy to Advance Rare Blood Disorder Treatments
Hemab Therapeutics posted on X:
”Hemab is growing fast, and we’re thrilled to announce our new Chief Operating Officer, Anant Murthy, PhD.
In this new role, Dr. Murthy will lead the company’s global efforts in market access, launch, and commercialization, bringing Hemab’s promising pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other neglected blood clotting disorders with high unmet needs to patients worldwide.
Read more here.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance
-
Nov 19, 2026, 12:56Batool Abuhalimeh: The Hidden Psychological Burden of Pulmonary Embolism
-
Nov 19, 2026, 12:45Pedro Perez: PE Recovery – From Acute Treatment to Long-Term Follow-Up
-
Nov 19, 2026, 12:34Edward Lee Carter: Are We Ready for FXIa Inhibitors?
-
Nov 19, 2026, 12:19Essama Telli: When a Bruise Doesn’t Heal – Recognising the Warning Signs
-
Nov 19, 2026, 11:51Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B